The Oncology Institute, Inc. (TOI) Q3 2025 Earnings Call Transcript

The Oncology Institute (TOI) reported robust Q3 2025 results, with total revenue increasing 36.7% year-over-year to $136.6 million, propelled by 57.4% growth in pharmacy revenue and 21% in patient services. The company significantly narrowed its adjusted EBITDA loss to $3.5 million, achieving its first adjusted EBITDA positive month in September, and reiterated its expectation for Q4 adjusted EBITDA positivity and free cash flow positivity by mid-2026. TOI raised its full-year 2025 revenue guidance to $495-$505 million and improved its adjusted EBITDA outlook, citing strong performance in its expanding delegated capitation model, including a doubled partnership with Elevance Health in Florida, and substantial operational efficiencies from AI implementation in areas like prior authorizations. Despite a recent cybersecurity incident affecting a vendor, the company anticipates minimal operational impact and has sufficient liquidity to manage temporary collection delays.

Analysis

The Oncology Institute (TOI) delivered robust Q3 2025 results, with total revenue increasing 36.7% year-over-year to $136.6 million, driven by a 57.4% surge in pharmacy revenue and 21% growth in patient services. The company significantly narrowed its adjusted EBITDA loss to $3.5 million, marking its first adjusted EBITDA positive month in September. This strong performance underpins a raised full-year 2025 revenue guidance to $495-$505 million and an improved adjusted EBITDA outlook, anticipating Q4 adjusted EBITDA positivity.

Growth was propelled by the expanding delegated capitation model, notably doubling its partnership with Elevance Health in Florida, and new contracts contributing an estimated $19 million in full-year revenue. TOI's pharmacy business continues to set records, further enhanced by the opening of a Florida pharmacy location. The company is also realizing substantial operational efficiencies through AI implementation, with prior authorization processes projected to yield up to $2 million in OpEx savings in 2026.

Despite a recent cybersecurity incident affecting a key vendor, management asserts minimal operational impact and sufficient liquidity to manage temporary collection delays in late Q4 and early Q1. TOI expects to achieve free cash flow positivity by mid-2026 and projects over 20% top-line growth for 2026, alongside subtle gross margin improvement. The company's ability to manage medical loss ratios (MLRs) in the high 60s across diverse contract types demonstrates effective risk management in value-based care.

Key Decisions for Investors

• Monitor TOI's Q4 adjusted EBITDA and 2026 free cash flow trajectory closely, as achieving these milestones is critical for sustained profitability and validates the company's operating model.
• Evaluate the scalability and margin maturation of the delegated capitation model, particularly the Elevance Health partnership, as this represents a significant growth driver and TAM expansion.
• Assess the impact of AI-driven operational efficiencies on future SG&A and gross margins, while also tracking the resolution and long-term implications of the cybersecurity incident on billing and collections.